Clinical and hematologic patterns, chemotherapy options in Polycythemia Vera

5^th World Congress on Cancer Therapy

September 28-30, 2015 Atlanta, USA

Larisa Musteata, Ion Corcimaru,Ion Mereuta and Vasile Musteata

State University of Medicine and Pharmacy â�?�?N. Testemitanuâ�?, Institute of Oncology, Republic of Moldova

Posters-Accepted Abstracts: J Cancer Sci Ther

Abstract :

The clinical and hematologic patterns, short- and long-term results of chemotherapy were analyzed in 92 patients with polycythemia vera during 25 yearsâ�?�? follow-up at the Institute of Oncology from Moldova. The patient age ranged between 29 â�?�? 74 years old, with the most frequently affected group of 50 â�?�? 59 years (38.0%). The median age was 54.2 �?± 2.13 years old. Males were 53 (57.6%), females â�?�? 39 (42.4%). The diagnosis was proved histologically by the bone marrow biopsy, which detected hypercellularity, erythroid and myeloid hyperplasia. The period disease onset â�?�? diagnosis varied between 1 â�?�? 7 months (median â�?�? 4 months). Stage IIA was revealed in 87 (96.7%) patients, stage IIB â�?�? in 5 (5.4%). Clinical examination and ultrasound scanning determined splenomegaly in 67 (72.8%) patients, and hepatomegaly in 46 (50.0%). Vascular thromboses occurred in 15 (16.3%) cases. The hemoglobin range was 180 â�?�? 230 g/l, erythrocyte count range â�?�? 5.5 â�?�? 6.5 x 1012/l, and platelet count range â�?�? 180.0 â�?�? 1620.0 x10 9/l. Busulfan was used as a front-line chemotherapy in 45 (48.9%) patients, and hydroxycarbamide â�?�? in 47 (51.1%) . Complete hematologic response was achieved in all 92 (100%) cases. Remission duration varied between 4 â�?�? 9 months (median â�?�? 6 months) in patients treated with busulfan, and between 3 â�?�? 8 months (median â�?�? 5 months) in those treated with hydroxycarbamide. The overall 10-year survival in busulfan-managed patients (86.9%) didnâ�?�?t exceed significantly (p�?�?0.05) that one achieved under hydroxycarbamide chemotherapy (85.2%). Chemotherapy decreases the probability of vascular complications, improves the life quality of patients, and approaches their median lifespan to that of population.

Biography :

Email: larisa.musteata@usmf.md